Rize Oncology Inc.
RIZE
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 169.70K | 134.20K | 107.00K | 147.90K | 183.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 178.00K | 134.90K | 117.00K | 159.10K | 339.20K |
| Operating Income | -178.00K | -134.90K | -117.00K | -159.10K | -339.20K |
| Income Before Tax | -170.20K | -128.70K | -107.80K | -144.20K | -316.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -170.20K | -128.70K | -107.80K | -144.20K | -316.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -170.20K | -128.70K | -107.80K | -144.20K | -316.20K |
| EBIT | -178.00K | -134.90K | -117.00K | -159.10K | -339.20K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 38.74M | 38.74M | 38.74M | 38.74M | 39.24M |
| Average Diluted Shares Outstanding | 38.74M | 38.74M | 38.74M | 38.74M | 39.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |